These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30981007)

  • 1. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance.
    Wu Y; Liu Y; Lu J; Cao Z; Jin Y; Ma L; Geng N; Ren S; Zheng Y; Shen C; Chen X
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):514-516.e2. PubMed ID: 30981007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.
    Seto WK; Cheung KS; Wong DK; Huang FY; Fung J; Liu KS; Lai CL; Yuen MF
    J Gastroenterol; 2016 May; 51(5):487-95. PubMed ID: 26446756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
    Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
    Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion.
    Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liu CH; Liao SH; Hong CM; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):581-590.e6. PubMed ID: 37871842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
    Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
    Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
    J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy.
    Liang M; Ma S; Hu X; Zhou B; Zhang J; Chen J; Wang Z; Sun J; Zhu X; Abbott W; Hou J
    Virol J; 2011 Feb; 8():69. PubMed ID: 21320337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
    Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
    J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.
    Alawad AS; Auh S; Suarez D; Ghany MG
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):700-709.e3. PubMed ID: 31323381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
    J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis.
    Yang YF; Zhao W; Xia HM; Zhong YD; Huang P; Wen J
    Antiviral Res; 2010 Feb; 85(2):361-5. PubMed ID: 19900483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.